- An advanced inhibitor
of advanced glycation end-products (A.G.E.s), a major causative factor
in diabetic kidney disease;
to animal models produces a dramatic protective effect against the onset
of diabetic kidney disease;
- Currently in
Phase II trials for diabetic kidney disease;
- Only 1 drug approved
for this disease;
- Estimated worldwide
market potential - greater than $6 billion.
Pyridorin™ is a small molecule drug candidate to treat diabetic kidney
disease. This drug candidate addresses
a tremendous medical problem. Four out of every ten patients with Type
1 diabetes, and 15% of patients with Type 2 diabetes will develop kidney
disease. Renal replacement therapy with either dialysis or kidney transplantation
is often the consequence of diabetic
kidney disease. BioStratum scientists have shown that Pyridorin™ prevents
hyperglycemia-induced damage to proteins and tissues, and dramatically
retards the progression of kidney disease in animal models of diabetes.
Phase I studies are complete, and no serious adverse events were seen,
indicating that Pyridorin™ is
a safe drug candidate. Phase II trials are ongoing.
Medicament cialis et viagra generiques en ligne en France.
- A recombinant
type IV collagen derived drug candidate;
- A potent anti-angiogenesis
and anti-tumor agent;
- Interrupts basal
- Unique mechanism
of action with multi-inhibitory activities;
- Soon entering
Angiocol™ is a recombinant type IV collagen derived
anti-angiogenesis drug candidate that inhibits new blood vessel growth
by targeting the assembly and organization of the basal lamina. Without
an increased blood supply,
the growth of a tumor is substantially limited. Therapies that inhibit
new blood vessel growth are a promising approach for the treatment of
cancer. Angiocol™ has demonstrated impressive anti-angiogenic and anti-tumor
activity in a wide range of test systems and animal models of cancer.
The Company believes that Angiocol's™ unique basal lamina targeted mode
of action, which intervenes in
a number of molecular processes important to new blood vessel growth,
will make it more effective than other drug candidates that are currently
undergoing development in this area. Pre-clinical toxicology studies are
underway and Phase I clinical trials are scheduled to begin in 2001.
More on Pyridorin™
More on Angiocol™